CXCR4 and breast cancer: Guo and co-workers found that NGAL siRNA-containing pH-dependent nanoliposomes coated with anti-CXCR-4 antibodies were delivered more efficiently and more specifically to metastatic breast cancer cell lines expressing high CXCR-4 levels respect to cell lines not expressing this chemokine receptor [100].